Aprea Therapeutics (APRE) Cash & Equivalents (2018 - 2026)

Aprea Therapeutics (APRE) has reported Cash & Equivalents for 9 consecutive years, with $46.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 141.06% year-over-year to $46.5 million; the TTM figure through Mar 2026 stood at $46.5 million (up 141.06% YoY), while the FY2025 annual figure was $14.6 million, down 36.11% from the prior year.
• Cash & Equivalents rose to $46.5 million in Q1 2026 per APRE's latest filing, from $14.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $47.7 million in Q1 2022 and bottomed at $13.7 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $27.9 million across 5 years, with a median of $27.7 million in 2023.
• Annual changes were most pronounced in 2025 — Cash & Equivalents sank 47.74% — and 2026, when it jumped 141.06%.
• Aprea Therapeutics' Cash & Equivalents stood at $28.8 million in 2022, then decreased by 24.94% to $21.6 million in 2023, then increased by 5.75% to $22.8 million in 2024, then tumbled by 36.11% to $14.6 million in 2025, then soared by 218.28% to $46.5 million in 2026.
• Business Quant data shows APRE's Cash & Equivalents at $46.5 million in Q1 2026, $14.6 million in Q4 2025, and $13.7 million in Q3 2025.